Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma
2018; Elsevier BV; Volume: 132; Issue: 1 Linguagem: Inglês
10.1182/blood-2017-11-815183
ISSN1528-0020
AutoresAnn S. LaCasce, R. Gregory Bociek, Ahmed Sawas, Paolo Caimi, Edward Agura, Jeffrey Matous, Stephen M. Ansell, Howland E. Crosswell, Miguel Islas‐Ohlmayer, Caroline Behler, Eric Cheung, Andres Forero‐Torres, Julie M. Vose, Owen A. O’Connor, Neil C. Josephson, Yinghui Wang, Ranjana H. Advani,
Tópico(s)Viral-associated cancers and disorders
ResumoKey Points The outpatient BV and bendamustine regimen is highly active as first salvage therapy in relapsed/refractory HL, with manageable toxicity. The CR rate of 73.6% exceeded those reported for standard chemotherapy regimens, and post-ASCT outcomes generally appeared excellent.
Referência(s)